Immunotherapy plus anlotinib after esophageal cancer surgery for residual tumor
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy and a drug called anlotinib (which helps stop blood vessel growth to tumors) after surgery for esophageal cancer. If you had some cancer left after surgery and it spread to lymph nodes, this treatment might help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of esophageal cancer called squamous cell carcinoma.
- You had chemotherapy combined with immunotherapy before your surgery, followed by complete removal of the tumor (called R0 resection).
- After surgery, pathology showed that some cancer cells were still present (more than 10% residual tumor) and that cancer had spread to at least one lymph node.
- It has been no more than 10 weeks since your surgery when you enroll.
- You are generally healthy enough to take oral medications and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether anlotinib tablets combined with an injection (TQB2450) can lower the risk of esophageal squamous cell cancer coming back after surgery. It may help by targeting cancer growth signals and blood-vessel formation to reduce recurrence.
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.